The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Cevostamab: FcRH5-CD3 Bispecific Antibody for Multiple Myeloma

Novel investigational target beyond BCMA for relapsed/refractory disease

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Cevostamab: FcRH5-CD3 Bispecific Antibody for Multiple Myeloma?

Cevostamab targets Fc receptor-like 5 (FcRH5/FCRL5), an antigen highly expressed on multiple myeloma cells with limited normal tissue distribution.

Provides a non-BCMA target option for patients who have relapsed after BCMA bispecifics, CAR-T cells, or antibody-drug conjugates.

Currently in late-phase clinical trials with promising response rates in heavily pretreated populations.

Single-dose step-up regimen followed by intravenous administration every three weeks reduces clinic visit frequency.

Combines T-cell engagement with FcRH5 specificity to address antigen escape mechanisms seen with BCMA targeting.

Symptoms

Cytokine release syndrome similar to other T-cell engagers: fever, hypotension during first cycles.
Neurotoxicity risk including ICANS-type symptoms requiring monitoring.
Cytopenias including neutropenia and thrombocytopenia after multiple cycles.
Infections due to immunosuppression and possible hypogammaglobulinemia.
Infusion-related reactions during intravenous administration.

Risk Factors

Prior exposure to BCMA-targeted therapies increases relevance for cevostamab consideration.
Heavy prior treatment burden with multiple drug classes.
High tumor burden at baseline raises CRS risk.
Active or recent infections at trial entry.
Significant cardiac or pulmonary comorbidities affecting tolerance.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Fever or chills within 24 to 72 hours of administration warrant immediate assessment.
  • New cognitive changes, headache, or focal neurological deficits.
  • Recurrent infections or unexplained fatigue suggesting cytopenia.
  • Bleeding episodes or unusual bruising during therapy.
  • Severe infusion-related reactions during administration.

Treatment Methods

01
Trial-based step-up dosing followed by 132 mg or higher target doses every three weeks (dose under refinement).
02
Premedication including corticosteroids, antihistamines, and antipyretics before each cycle.
03
CRS management with tocilizumab and supportive care per institutional protocols.
04
Infection prophylaxis: PJP prophylaxis, antiviral coverage, and IVIG when indicated.
05
Continued enrollment in clinical trials provides access while regulatory approval pending.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.